tbc-11251 has been researched along with Subarachnoid Hemorrhage in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arthur, AS; Helm, GA; Kassell, NF; Lee, KS; Louis, HG; Wanebo, JE; West, K | 1 |
| Wu-Wong, JR | 1 |
2 review(s) available for tbc-11251 and Subarachnoid Hemorrhage
| Article | Year |
|---|---|
Systemic administration of the endothelin-A receptor antagonist TBC 11251 attenuates cerebral vasospasm after experimental subarachnoid hemorrhage: dose study and review of endothelin-based therapies in the literature on cerebral vasospasm.
Topics: Animals; Basilar Artery; Calcium Signaling; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Endothelin Receptor Antagonists; Endothelin-1; Infusions, Intravenous; Ischemic Attack, Transient; Isoxazoles; Male; Rabbits; Receptor, Endothelin A; Subarachnoid Hemorrhage; Thiophenes | 1998 |
Sitaxsentan (ICOS-Texas Biotechnology).
Topics: Animals; Clinical Trials as Topic; Endothelin Receptor Antagonists; Heart Failure; Humans; Isoxazoles; Lung Diseases, Obstructive; Receptor, Endothelin A; Subarachnoid Hemorrhage; Thiophenes | 2001 |